{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:43:45Z","timestamp":1781855025766,"version":"3.54.5"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The increasing reliance on accelerated approvals and surrogate endpoints for Food and Drug Administration (FDA) approvals of gastrointestinal (GI) cancer therapies raises concerns about their clinical benefit and long-term patient outcomes. The shift toward single-arm trials in regulatory decisions further complicates treatment evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods<\/jats:title>\n                    <jats:p>This retrospective observational study evaluated all FDA approvals for GI cancer therapies from January 2006 through January 2025. Data were extracted from FDA archives, ClinicalTrials.gov, and PubMed. Approvals were categorized by regulatory pathway (accelerated vs regular), trial design (single-arm vs randomized), and primary endpoint (surrogate vs overall survival [OS]). Clinical benefit was assessed based on OS improvement and the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). The primary outcome was the proportion of approvals based on surrogate versus OS endpoints. Secondary outcomes included use of single-arm designs, frequency of accelerated approvals, OS gain, and the proportion meeting ESMO-MCBS substantial benefit (score \u2265 4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The FDA granted 60 GI cancer drug approvals from 67 trials. Approvals rose from 15 (25%) in 2006-2014 to 45 (75%) in 2015-2025. Single-arm trials increased to 24%, and surrogate endpoints were used in 41.8% (ORR 20.9%, PFS 19.4%). Median OS improvement was 2.1\u2009months (IQR: 1.6-2.65). Only 24.3% of trials met ESMO-MCBS substantial benefit. Of 15 accelerated approvals, 66.7% remained pending, 13.3% received full approval, and 20% were withdrawn.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Expedited approvals have improved drug access in GI oncology, but modest benefits highlight the need to balance speed with outcomes that truly matter to patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf381","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T12:56:00Z","timestamp":1765025760000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluating Food and Drug Administration approved  gastrointestinal cancer drugs: clinical benefit and trial endpoints over the past two decades"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6286-3855","authenticated-orcid":false,"given":"Fares","family":"Jamal","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oudai","family":"Sahvan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Luiz Serrano Uson","family":"Junior","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy C","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Jacksonville, FL 32224,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1267-8735","authenticated-orcid":false,"given":"Fang-Shu","family":"Ou","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Biostatistics, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6931-242X","authenticated-orcid":false,"given":"Mohamad Bassam","family":"Sonbol","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Mayo Clinic Cancer Center, Mayo Clinic , Phoenix, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"2025121103131624000_oyaf381-B1","author":"(FDA) USFaDA","year":"2024"},{"key":"2025121103131624000_oyaf381-B2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1200\/JCO.2007.13.8156","article-title":"Reflections on medical oncology: 25 years of clinical trials\u2014where have we come and where are we going?","volume":"26","author":"Booth","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025121103131624000_oyaf381-B3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamainternmed.2018.8351","article-title":"Estimation of study time reduction using surrogate end points rather than overall survival in oncology clinical trials","volume":"179","author":"Chen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025121103131624000_oyaf381-B4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1001\/jama.2017.9415","article-title":"Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US food and drug administration","volume":"318","author":"Naci","year":"2017","journal-title":"JAMA"},{"key":"2025121103131624000_oyaf381-B5","author":"(FDA)","year":"2024"},{"key":"2025121103131624000_oyaf381-B6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025121103131624000_oyaf381-B7","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-magnitude of clinical benefit scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"key":"2025121103131624000_oyaf381-B8","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/cam4.2058","article-title":"Anticancer drugs approved by the food and drug administration for gastrointestinal malignancies: clinical benefit and price considerations","volume":"8","author":"Jiang","year":"2019","journal-title":"Cancer Med"},{"key":"2025121103131624000_oyaf381-B9","author":"(NCI) NCI","year":"2024"},{"key":"2025121103131624000_oyaf381-B10","author":"Administration USFaD","year":"2025"},{"key":"2025121103131624000_oyaf381-B11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121103131624000_oyaf381-B12","author":"(FDA) USFaDA","year":"2024"},{"key":"2025121103131624000_oyaf381-B13","author":"(FDA) USFaDA","year":"2024"},{"key":"2025121103131624000_oyaf381-B14","author":"Administration USFaD","year":"2025"},{"key":"2025121103131624000_oyaf381-B15","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"2025121103131624000_oyaf381-B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"2025121103131624000_oyaf381-B17","author":"(FDA) USFaDA","year":"2024"},{"key":"2025121103131624000_oyaf381-B18","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025121103131624000_oyaf381-B19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","article-title":"Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial","volume":"392","author":"Shitara","year":"2018","journal-title":"Lancet"},{"key":"2025121103131624000_oyaf381-B20","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025121103131624000_oyaf381-B21","author":"(FDA) USFaDA","year":"2024"},{"key":"2025121103131624000_oyaf381-B22","author":"(FDA) USFaDA","year":"2024"},{"key":"2025121103131624000_oyaf381-B23","author":"(FDA) USFaDA","year":"2024"},{"key":"2025121103131624000_oyaf381-B24","author":"(FDA) USFaDA","year":"2024"},{"key":"2025121103131624000_oyaf381-B25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121103131624000_oyaf381-B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"2025121103131624000_oyaf381-B27","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-Mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"2025121103131624000_oyaf381-B28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"2025121103131624000_oyaf381-B29","year":"2025"},{"key":"2025121103131624000_oyaf381-B30","author":"Publishers","year":"2025"},{"key":"2025121103131624000_oyaf381-B31","doi-asserted-by":"publisher","first-page":"103654","DOI":"10.1016\/j.esmoop.2024.103654","article-title":"Association between health-related quality-of-life results, outcomes of efficacy and drug approvals: a meta-research study of randomized phase III trials in oncology","volume":"9","author":"Paratore","year":"2024","journal-title":"ESMO Open"},{"key":"2025121103131624000_oyaf381-B32","doi-asserted-by":"publisher","first-page":"102824","DOI":"10.1016\/j.eclinm.2024.102824","article-title":"Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward","volume":"76","author":"Mittal","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025121103131624000_oyaf381-B33","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the randomized clinical trial in the era of precision oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025121103131624000_oyaf381-B34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.7326\/M23-2515","article-title":"The benefits and risks of receiving investigational solid tumor drugs in randomized trials: a systematic review and meta-analysis","volume":"177","author":"Iskander","year":"2024","journal-title":"Ann Intern Med"},{"key":"2025121103131624000_oyaf381-B35","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","article-title":"American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes","volume":"32","author":"Ellis","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025121103131624000_oyaf381-B36","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1093\/jnci\/djad096","article-title":"Consensus report of the 2021 national cancer institute neuroendocrine tumor clinical trials planning meeting","volume":"115","author":"Singh","year":"2023","journal-title":"J Natl Cancer Inst"},{"key":"2025121103131624000_oyaf381-B37","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djab187","article-title":"Reevaluating disease-free survival as an endpoint vs overall survival in stage III adjuvant colon cancer trials","volume":"114","author":"Yin","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2025121103131624000_oyaf381-B38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejca.2015.10.014","article-title":"Observer variability in RECIST-based tumour burden measurements: a meta-analysis","volume":"53","author":"Yoon","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025121103131624000_oyaf381-B39","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1001\/jamaoncol.2022.7842","article-title":"Requirements for meaningful progress in the therapy of neuroendocrine cancers","volume":"9","author":"Labadie","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025121103131624000_oyaf381-B40","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1016\/j.ejca.2015.07.005","article-title":"The role of censoring on progression free survival: oncologist discretion advised","volume":"51","author":"Prasad","year":"2015","journal-title":"Eur J Cancer"},{"key":"2025121103131624000_oyaf381-B41","doi-asserted-by":"publisher","first-page":"114022","DOI":"10.1016\/j.ejca.2024.114022","article-title":"Progression-free survival estimates are shaped by specific censoring rules: implications for PFS as an endpoint in cancer randomized trials","volume":"202","author":"Lesan","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025121103131624000_oyaf381-B42","doi-asserted-by":"publisher","first-page":"113503","DOI":"10.1016\/j.ejca.2023.113503","article-title":"Objective response rate and progression-free survival as surrogates for overall survival treatment effect: a meta-analysis across diverse tumour groups and contemporary therapies","volume":"198","author":"Shahnam","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025121103131624000_oyaf381-B43","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1001\/jamainternmed.2018.4710","article-title":"Evaluating progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis","volume":"178","author":"Kovic","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025121103131624000_oyaf381-B44","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-Year experience of US food and drug administration accelerated approval of malignant hematology and oncology drugs and biologics: a review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025121103131624000_oyaf381-B45","doi-asserted-by":"publisher","first-page":"e2343285","DOI":"10.1001\/jamanetworkopen.2023.43285","article-title":"National comprehensive cancer network guideline recommendations of cancer drugs with accelerated approval","volume":"6","author":"Cliff","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025121103131624000_oyaf381-B46","doi-asserted-by":"publisher","first-page":"n1959","DOI":"10.1136\/bmj.n1959","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"key":"2025121103131624000_oyaf381-B47","author":"Gyawali"},{"key":"2025121103131624000_oyaf381-B48","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejca.2021.06.058","article-title":"Nested and adjacent subgroups in cancer clinical trials: when the best interests of companies and patients diverge","volume":"155","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025121103131624000_oyaf381-B49","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025121103131624000_oyaf381-B50","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025121103131624000_oyaf381-B51","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"key":"2025121103131624000_oyaf381-B52","author":"Ryan"},{"key":"2025121103131624000_oyaf381-B53","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025121103131624000_oyaf381-B54","author":"Hahn"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf381\/65800630\/oyaf381.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf381\/65800630\/oyaf381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/12\/oyaf381\/65800630\/oyaf381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:13:26Z","timestamp":1765440806000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf381\/8373897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf381","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,12,1]]},"article-number":"oyaf381"}}